Kilitch Drugs Key Ratios
NSE: KILITCH | BSE: 524500
₹248.04
As on 09-Oct-2026 13:19IST
Market cap
₹868 Cr
Revenue (TTM)
₹237 Cr
P/E Ratio
28.9
P/B Ratio
3.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -49.91 | 4.03 | 14.04 | 18.46 | 24.93 |
| EBIT | -91.30 | -23.92 | 9.51 | 24.45 | 43.84 |
| Net Profit | -79.94 | -3.67 | 7.34 | 36.87 | 37.16 |
| EPS | -79.94 | -9.50 | 0.89 | 32.68 | 34.47 |
| Book Value | -- | -- | 30.00 | 20.27 | 14.82 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-26 | Mar-25 |
| EBIT-Margin
| 15.71 | 11.90 | 13.66 | 14.31 | 14.44 |
| Net Margin
| 14.90 | 8.70 | 11.74 | 11.96 | 11.91 |
| Return on equity
| 10.90 | 8.89 | 11.02 | 12.26 | 13.20 |
| Return on Capital
| 12.87 | 12.53 | -- | 14.50 | 17.31 |
| Return on Assets
| 7.97 | 5.95 | 7.58 | 7.73 | 9.11 |
| Debt to Equity (x)
| -- | -- | 0.21 | 0.32 | 0.24 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
--
|
14.50
|
17.31
|
13.30
|
10.26
|
|
Peer Median
|
--
|
21.34
|
21.76
|
21.89
|
--
|
ROE
11.02
Lower than Peers by 4.43
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
11.02
|
12.26
|
13.20
|
8.43
|
5.86
|
|
Peer Median
|
15.45
|
18.24
|
17.93
|
16.42
|
--
|
ROA
7.58
Lower than Peers by 2.97
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
7.58
|
7.73
|
9.11
|
5.97
|
3.89
|
|
Peer Median
|
10.55
|
10.51
|
12.81
|
12.32
|
--
|
EBIT Margin
13.66
Lower than Peers by 4.00
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
13.66
|
14.31
|
14.44
|
13.55
|
10.16
|
|
Peer Median
|
17.65
|
18.18
|
18.93
|
21.05
|
--
|
Net Margin
11.74
Lower than Peers by 2.22
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
11.74
|
11.96
|
11.91
|
8.55
|
5.81
|
|
Peer Median
|
13.95
|
13.32
|
14.94
|
15.51
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
--
|
14.07
|
14.14
|
10.96
|
8.48
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
14.04
Higher than Peers by 2.11
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
14.04
|
18.74
|
28.47
|
10.58
|
22.20
|
|
Peer Median
|
11.93
|
11.99
|
10.90
|
13.44
|
--
|
EBIT Growth
9.51
Lower than Peers by 12.45
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
9.51
|
17.71
|
36.93
|
47.48
|
76.44
|
|
Peer Median
|
21.96
|
15.05
|
15.01
|
23.50
|
--
|
Net Profit Growth
7.34
Lower than Peers by 16.22
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
7.34
|
18.28
|
83.72
|
63.90
|
33.30
|
|
Peer Median
|
23.56
|
11.28
|
14.80
|
30.12
|
--
|
EPS Growth
0.89
Lower than Peers by 18.79
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
0.89
|
6.21
|
82.86
|
35.41
|
41.82
|
|
Peer Median
|
19.69
|
12.16
|
14.27
|
29.02
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
--
|
38.28
|
14.80
|
20.30
|
7.35
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.21
Higher than Peers by 0.20
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
0.21
|
0.32
|
0.24
|
0.18
|
0.15
|
|
Peer Median
|
0.01
|
0.05
|
0.06
|
0.03
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
--
|
0.11
|
0.11
|
0.18
|
0.15
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.83
Lower than Peers by 0.19
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
1.83
|
1.83
|
2.06
|
2.27
|
1.84
|
|
Peer Median
|
2.02
|
1.93
|
1.90
|
2.23
|
--
|
Quick Ratio
1.73
Higher than Peers by 0.24
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
1.73
|
1.73
|
1.88
|
2.21
|
1.81
|
|
Peer Median
|
1.49
|
1.52
|
1.46
|
1.59
|
--
|
Interest Coverage
8.96
Lower than Peers by 10.06
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
8.96
|
7.14
|
7.48
|
4.21
|
3.36
|
|
Peer Median
|
19.02
|
19.95
|
24.96
|
45.29
|
--
|
Operating Efficiency
Debtors to sales
50.66
Higher than Peers by 29.50
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
50.66
|
51.04
|
42.73
|
40.96
|
38.89
|
|
Peer Median
|
21.16
|
19.87
|
21.77
|
20.10
|
--
|
Asset Turnover
0.62
Lower than Peers by 0.11
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
0.62
|
0.62
|
0.72
|
0.68
|
0.66
|
|
Peer Median
|
0.73
|
0.78
|
0.76
|
0.81
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
--
|
158.82
|
136.16
|
138.92
|
125.11
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
--
|
20.79
|
17.76
|
7.13
|
9.21
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
--
|
193.60
|
139.16
|
153.61
|
204.43
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
--
|
-13.99
|
14.76
|
-7.56
|
-70.11
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
28.89
Lower than Peers by 2.39
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
28.89
|
14.78
|
10.65
|
42.02
|
20.81
|
|
Peer Median
|
31.28
|
32.39
|
26.81
|
39.85
|
--
|
Price / Book Value
3.09
Lower than Peers by 1.78
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
3.09
|
1.60
|
2.88
|
3.56
|
1.49
|
|
Peer Median
|
4.86
|
5.16
|
4.65
|
6.11
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.60
|
0.61
|
0.61
|
0.37
|
--
|
EV/EBITDA
19.65
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
19.65
|
10.66
|
14.47
|
22.23
|
10.64
|
|
Peer Median
|
--
|
26.23
|
27.02
|
34.57
|
--
|
Market Cap
868
Lower than Peers by 16,285
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Kilitch Drugs
|
868
|
446
|
581
|
627
|
217
|
|
Peer Median
|
17,153
|
15,102
|
20,914
|
25,297
|
--
|